<?xml version="1.0" encoding="UTF-8"?>
<html><body class="spl" id="spl">
<div class="DocumentTitle"><p class="DocumentTitle"><strong>TRIMETHOPRIMÂ - trimethoprimÂ tabletÂ </strong><br>Physicians Total Care, Inc.<br></p></div>
<h1>Trimethoprim<br>Tablets USP<br>Revised: June 2006<br>Rx only</h1>
<div class="Contents">
<div class="Section" data-sectionCode="48780-1">
<a name="section-1"></a><p></p>
</div>
<div class="Section" data-sectionCode="34089-3">
<a name="LINK_ea601eaa-4e62-4887-a44a-571f31437888"></a><a name="section-1"></a><p></p>
<h1>DESCRIPTION</h1>
<p class="First">Trimethoprim is a synthetic antibacterial available as 100 mg tablets for oral administration.</p>
<p>Trimethoprim is 2,4-Diamino-5-(3,4,5-trimethoxybenzyl) pyrimidine. It is a white to cream colored, odorless, bitter compound. The structural formula is represented below:</p>
<div class="Figure">
<img alt="Trimethoprim Structural Formula" src="http://dailymed.nlm.nih.gov/dailymed/image.cfm?setid=7d25e3f9-7b0d-452d-953e-f100bb0f2db7&amp;name=trimethoprim-tablets-1.jpg"><p class="MultiMediaCaption"></p>
</div>
<p>C<span class="Sub">14</span>H<span class="Sub">18</span>N<span class="Sub">4</span>O<span class="Sub">3</span>â€ƒâ€ƒâ€ƒâ€ƒâ€ƒâ€ƒM.W. 290.32</p>
<p>Trimethoprim Tablets USP, 100 mg contain the following inactive ingredients: anhydrous lactose, colloidal silicon dioxide, magnesium stearate, sodium lauryl sulfate, sodium starch glycolate and stearic acid.</p>
</div>
<div class="Section" data-sectionCode="34090-1">
<a name="LINK_f4010b65-f35c-49fc-8927-9aab12e895fd"></a><a name="section-2"></a><p></p>
<h1>CLINICAL PHARMACOLOGY</h1>
<p class="First">Trimethoprim is rapidly absorbed following oral administration. It exists in the blood as unbound, protein-bound and metabolized forms. Ten to twenty percent of trimethoprim is metabolized, primarily in the liver; the remainder is excreted unchanged in the urine. The principal metabolites of trimethoprim are the 1- and 3-oxides and the 3'- and 4'-hydroxy derivatives. The free form is considered to be the therapeutically active form. Approximately 44% of trimethoprim is bound to plasma proteins.</p>
<p>Mean peak plasma concentrations of approximately 1 mcg/mL occur 1 to 4 hours after oral administration of a single 100 mg dose. A single 200 mg dose will result in serum levels approximately twice as high. The half-life of trimethoprim ranges from 8 to 10 hours. However, patients with severely <span class="product-label-link" type="condition" conceptid="4030518" conceptname="Renal impairment">impaired renal function</span> exhibit an increase in the half-life of trimethoprim, which requires either dosage regimen adjustment or not using the drug in such patients (see<span class="Bold"><a href="#LINK_7bba4444-18dd-4b9d-a51e-5cdb97a597ea">DOSAGE AND ADMINISTRATION</a></span>). During a 13-week study of trimethoprim administered at a daily dosage of 200 mg (50 mg q.i.d.), the mean minimum steady-state concentration of the drug was 1.1 mcg/mL. Steady-state concentrations were achieved within 2 to 3 days of chronic administration, and were maintained throughout the experimental period.</p>
<p>Excretion of trimethoprim is primarily by the kidneys through glomerular filtration and tubular secretion. Urine concentrations of trimethoprim are considerably higher than are the concentrations in the blood. After a single oral dose of 100 mg, urine concentrations of trimethoprim ranged from 30 to 160 mcg/mL during the 0- to 4-hour period and declined to approximately 18 to 91 mcg/mL during the 8- to 24-hour period. A 200 mg single oral dose will result in trimethoprim urine levels approximately twice as high. After oral administration, 50% to 60% of trimethoprim is excreted in the urine within 24 hours, approximately 80% of this being unmetabolized trimethoprim.</p>
<p>Since normal vaginal and fecal flora are the source of most pathogens causing <span class="product-label-link" type="condition" conceptid="81902" conceptname="Urinary tract infectious disease">urinary tract infections</span>, it is relevant to consider the distribution of trimethoprim into these sites. Concentrations of trimethoprim in vaginal secretions are consistently greater than those found simultaneously in the serum, being typically 1.6 times the concentrations of simultaneously obtained serum samples. Sufficient trimethoprim is excreted in the feces to markedly reduce or eliminate trimethoprim-susceptible organisms from the fecal flora.</p>
<p>Trimethoprim also passes the placental barrier and is excreted in human milk.</p>
<div class="Section" data-sectionCode="42229-5">
<a name="LINK_f9f48f94-e873-42c7-b649-e93bafaa7e1c"></a><a name="section-2.1"></a><p></p>
<h2>Microbiology</h2>
<p class="First">Trimethoprim blocks the production of tetrahydrofolic acid from dihydrofolic acid by binding to and reversibly inhibiting the required enzyme, dihydrofolate reductase. This binding is much stronger for the bacterial enzyme than for the corresponding mammalian enzyme. Thus, trimethoprim selectively interferes with bacterial biosynthesis of nucleic acids and proteins.</p>
<p><span class="Italics">In vitro </span>serial dilution tests have shown that the spectrum of antibacterial activity of trimethoprim includes the common urinary tract pathogens with the exception of <span class="Italics">Pseudomonas aeruginosa.</span></p>
<p>The dominant non-<span class="Italics">Entero-bacteriaceae </span>fecal organisms, <span class="Italics">Bacteroides </span>spp. and <span class="Italics">Lactobacillus </span>spp., are not susceptible to trimethoprim concentrations obtained with the recommended dosage.</p>
<p>Trimethoprim has been shown to be active against most <span class="product-label-link" type="condition" conceptid="4168796" conceptname="Muscle strain">strains</span> of the following microorganisms, both <span class="Italics">in vitro </span>and in clinical <span class="product-label-link" type="condition" conceptid="432250" conceptname="Infectious disease">infections</span> as described in the<span class="Bold"><a href="#LINK_216cdadc-bb0d-4656-963b-42978b95cc5c">INDICATIONS AND USAGE</a></span> section.</p>
</div>
<div class="Section" data-sectionCode="42229-5">
<a name="LINK_b1c05534-93a2-4752-bb50-c34d7e0948bc"></a><a name="section-2.2"></a><p></p>
<h2>Aerobic gram-positive microorganisms</h2>
<p class="First"><span class="Italics">Staphylococcus </span>species (coagulase-negative <span class="product-label-link" type="condition" conceptid="4168796" conceptname="Muscle strain">strains</span>, including <span class="Italics">S. saprophyticus</span>)</p>
</div>
<div class="Section" data-sectionCode="42229-5">
<a name="LINK_f3b88e15-3980-43e6-bb1e-101a1b54be35"></a><a name="section-2.3"></a><p></p>
<h2>Aerobic gram-negative microorganisms</h2>
<p class="First"><span class="Italics">Enterobacter species</span><br><span class="Italics">Escherichia coli</span><br><span class="Italics">Klebsiella pneumoniae</span><br><span class="Italics">Proteus mirabilis</span><br><span class="Italics">Susceptibility Testing Methods</span></p>
<p><span class="Bold"><span class="Underline">Dilution Techniques:</span></span></p>
<p>Quantitative methods are used to determine antimicrobial minimal inhibitory concentrations (MICs). These MICs provide estimates of the susceptibility of bacteria to antimicrobial compounds. The MICs should be determined using a standardized procedure. Standardized procedures are based on a dilution method<span class="Sup">1</span> (broth or agar) or equivalent with standardized inoculum concentrations and standardized concentrations of trimethoprim powder. The MIC values should be interpreted according to the following criteria:</p>
<p>For testing <span class="Italics">Enterobacteri-aceae </span>and <span class="Italics">Staphylococcus </span>spp.:</p>
<a name="i15e140ac-ba60-402a-8620-3b2f4ddd7296"></a><table frame="void">
<col width="295">
<col width="295">
<tbody class="Headless">
<tr class="First">
<td align="center" valign="top">Â <span class="Underline">MIC (mcg/mL)</span>
</td>
<td align="center" valign="top">Â <span class="Underline">Interpretation</span>
</td>
</tr>
<tr>
<td align="center" valign="top">Â â‰¤8</td>
<td align="center" valign="top">Â Susceptible (S)</td>
</tr>
<tr class="Last">
<td align="center" valign="top">Â Â â‰¥16</td>
<td align="center" valign="top">Â Resistant (R)</td>
</tr>
</tbody>
</table>
<p>A report of â€œSusceptibleâ€? indicates that the pathogen is likely to be inhibited if the antimicrobial compound in the blood reaches the concentrations usually achievable. A report of â€œIntermediateâ€? indicates that the result should be considered equivocal, and, if the microorganism is not fully susceptible to alternative, clinically feasible drugs, the test should be repeated. This category implies possible clinical applicability in body sites where the drug is physiologically concentrated or in situations where high dosage of drug can be used. This category also provides a buffer zone which prevents small uncontrolled technical factors from causing major discrepancies in interpretation. A report of â€œResistantâ€? indicates that the pathogen is not likely to be inhibited if the antimicrobial compound in the blood reaches the concentrations usually achievable; other therapy should be selected. Standardized susceptibility test procedures require the use of laboratory control microorganisms to control the technical aspects of the laboratory procedures. Standard trimethoprimÂª powder should provide the following MIC values:</p>
<a name="i41733f8a-e590-44d8-89ed-677f916f2dee"></a><table frame="void">
<col width="295">
<col width="295">
<tbody class="Headless">
<tr class="First">
<td valign="top">Â <span class="Underline">Microorganism</span>
</td>
<td align="center" valign="top">Â <span class="Underline">MIC (mcg/mL)</span>
</td>
</tr>
<tr>
<td valign="top">Â <span class="Italics">E. coli </span>ATCC 25922</td>
<td align="center" valign="top">Â 0.5 - 2.0</td>
</tr>
<tr>
<td valign="top">Â <span class="Italics">S. aureus </span>ATCC 29213</td>
<td align="center" valign="top">Â 1.0 - 4.0</td>
</tr>
<tr class="Last">
<td valign="top">Â ÂªVery medium-dependent.</td>
<td align="center" valign="top">Â </td>
</tr>
</tbody>
</table>
<p><span class="Bold"><span class="Underline">Diffusion Techniques: </span></span>Quantitative methods that require measurement of zone diameters also provide reproducible estimates of the susceptibility of bacteria to antimicrobial compounds. One such standardized procedure<span class="Sup">2</span> requires the use of standardized inoculum concentrations. This procedure uses paper disks impregnated with 5 mcg trimethoprim to test the susceptibility of microorganisms to trimethoprim.</p>
<p>Reports from the laboratory providing results of the standard single-disk susceptibility test with a 5 mcg trimethoprim disk should be interpreted according to the following criteria:</p>
<p>For testing <span class="Italics">Enterobacteri-aceae </span>and <span class="Italics">Staphylococcus </span>spp.:</p>
<a name="i90dee9ce-0542-4df1-8d67-da92b7c9ff3f"></a><table frame="void">
<col width="295">
<col width="295">
<tbody class="Headless">
<tr class="First">
<td align="center" valign="top">Â Zone</td>
<td align="center" valign="top">Â </td>
</tr>
<tr>
<td align="center" valign="top">Â <span class="Underline">Diameter (mm)</span>
</td>
<td align="center" valign="top">Â <span class="Underline">Interpretation</span>
</td>
</tr>
<tr>
<td align="center" valign="top">Â â‰¥16</td>
<td align="center" valign="top">Â Susceptible (S)</td>
</tr>
<tr>
<td align="center" valign="top">Â 11-15</td>
<td align="center" valign="top">Â Intermediate (I)</td>
</tr>
<tr class="Last">
<td align="center" valign="top">Â â‰¤10</td>
<td align="center" valign="top">Â Resistant (R)</td>
</tr>
</tbody>
</table>
<p>Interpretation should be as stated above for results using dilution techniques. Interpretation involves correlation of the diameter obtained in the disk test with the MIC for trimethoprim.</p>
<p>As with standardized dilution techniques, diffusion methods require the use of laboratory control microorganisms that are used to control the technical aspects of the laboratory procedures. For the diffusion technique, the 5 mcg trimethoprim disk<span class="Sup">b</span> should provide the following zone diameters in these laboratory test quality control <span class="product-label-link" type="condition" conceptid="4168796" conceptname="Muscle strain">strains</span>.</p>
<a name="i01c955a8-963b-4cf4-8087-9a9d65d0149e"></a><table frame="void">
<col width="295">
<col width="295">
<tbody class="Headless">
<tr class="First">
<td valign="top">Â <span class="Underline">Microorganism</span>
</td>
<td align="center" valign="top">Â <span class="Underline">MIC (mcg/mL)</span>
</td>
</tr>
<tr>
<td valign="top">Â <span class="Italics">E. coli </span>ATCC 25922</td>
<td align="center" valign="top">Â 0.5 - 2.0</td>
</tr>
<tr>
<td valign="top">Â </td>
<td align="center" valign="top">Â <span class="Underline">Zone</span>
</td>
</tr>
<tr>
<td valign="top">Â <span class="Underline">Microorganism</span>
</td>
<td align="center" valign="top">Â <span class="Underline">Diameter (mm)</span>
</td>
</tr>
<tr>
<td valign="top">Â <span class="Italics">E. coli </span>ATCC 25922</td>
<td align="center" valign="top">Â 21 â€“ 28</td>
</tr>
<tr class="Last">
<td valign="top">Â <span class="Italics">S. aureus </span>ATCC 25923</td>
<td align="center" valign="top">Â 19 â€“ 26</td>
</tr>
</tbody>
</table>
<p><span class="Sup">b</span>Mueller-Hinton agar should be checked for excessive levels of thymidine. To determine whether Mueller-Hinton medium has sufficiently low levels of thymidine and thymine, an <span class="Italics">Enterococcus faecalis </span>(ATCC 29212 or ATCC 33186) may be tested with trimethoprim/sulfamethoxazole disks. A zone of inhibition â‰¥20 mm that is essentially free of fine colonies indicates a sufficiently low level of thymidine and thymine.</p>
</div>
</div>
<div class="Section" data-sectionCode="34067-9">
<a name="LINK_216cdadc-bb0d-4656-963b-42978b95cc5c"></a><a name="section-3"></a><p></p>
<h1>INDICATIONS AND USAGE</h1>
<p class="First">For the treatment of initial episodes of uncomplicated <span class="product-label-link" type="condition" conceptid="81902" conceptname="Urinary tract infectious disease">urinary tract infections</span> due to susceptible <span class="product-label-link" type="condition" conceptid="4168796" conceptname="Muscle strain">strains</span> of the following organisms: <span class="Italics">Escherichiacoli, Proteus mirabilis, Klebsiella pneumoniae, Enterobacter </span>species and coagulase-negative <span class="Italics">Staphylococcus </span>species, including <span class="Italics">S. saprophyticus.</span></p>
<p>Cultures and susceptibility tests should be performed to determine the susceptibility of the bacteria to trimethoprim. Therapy may be initiated prior to obtaining the results of these tests.</p>
</div>
<div class="Section" data-sectionCode="34070-3">
<a name="LINK_78df9eac-a627-4704-b3cd-89b01ba2837c"></a><a name="section-4"></a><p></p>
<h1>CONTRAINDICATIONS</h1>
<p class="First">Trimethoprim tablets are contraindicated in individuals hypersensitive to trimethoprim and in those with documented <span class="product-label-link" type="condition" conceptid="435789" conceptname="Megaloblastic anemia">megaloblastic anemia</span> due to <span class="product-label-link" type="condition" conceptid="4101280" conceptname="Folic acid deficiency">folate deficiency</span>.</p>
</div>
<div class="Section" data-sectionCode="34071-1">
<a name="LINK_a8e3f1b5-109b-49d8-98e2-8c3465fc1c90"></a><a name="section-5"></a><p></p>
<h1>WARNINGS</h1>
<p class="First">Serious <span class="product-label-link" type="condition" conceptid="4084167" conceptname="Acute allergic reaction">hypersensitivity reactions</span> have been reported rarely in patients on trimethoprim therapy. Trimethoprim has been reported rarely to interfere with hematopoiesis, especially when administered in large doses and/or for <span class="product-label-link" type="condition" conceptid="4088438" conceptname="Prolonged periods">prolonged periods</span>.</p>
<p>The presence of clinical signs such as <span class="product-label-link" type="condition" conceptid="26711" conceptname="Chronic pharyngitis">sore throat</span>, <span class="product-label-link" type="condition" conceptid="437663" conceptname="Fever">fever</span>, <span class="product-label-link" type="condition" conceptid="4260836" conceptname="Blanching of skin">pallor</span> or <span class="product-label-link" type="condition" conceptid="4047773" conceptname="Purpura">purpura</span> may be early indications of serious <span class="product-label-link" type="condition" conceptid="40528016" conceptname="Disorder of hematopoietic system">blood disorders</span> (see<span class="Bold"><a href="#LINK_c2fd41ae-b8ab-45de-a22b-05a09bdcfe67">OVERDOSAGE: Chronic</a></span>). Complete blood counts should be obtained if any of these signs are noted in a patient receiving trimethoprim and the drug discontinued if a significant reduction in the count of any formed blood element is found.</p>
</div>
<div class="Section" data-sectionCode="42232-9">
<a name="LINK_a78266d8-df55-4de0-921a-a964038fa3ed"></a><a name="section-6"></a><p></p>
<h1>PRECAUTIONS</h1>
<div class="Section" data-sectionCode="34072-9">
<a name="LINK_4a23e082-8d5f-4ccb-bedb-89a3adda415b"></a><a name="section-6.1"></a><p></p>
<h2>General</h2>
<p class="First">Trimethoprim should be given with caution to patients with possible <span class="product-label-link" type="condition" conceptid="4101280" conceptname="Folic acid deficiency">folate deficiency</span>. Folates may be administered concomitantly without interfering with the antibacterial action of trimethoprim. Trimethoprim should also be given with caution to patients with impaired renal or hepatic function (see<span class="Bold"><a href="#LINK_f4010b65-f35c-49fc-8927-9aab12e895fd">CLINICAL PHARMACOLOGY</a></span> and<span class="Bold"><a href="#LINK_7bba4444-18dd-4b9d-a51e-5cdb97a597ea">DOSAGE AND ADMINISTRATION</a></span>).</p>
</div>
<div class="Section" data-sectionCode="34073-7">
<a name="LINK_f5e32cb0-e88b-40ef-8c65-a006086967f5"></a><a name="section-6.2"></a><p></p>
<h2>Drug Interactions</h2>
<p class="First">Trimethoprim may inhibit the hepatic metabolism of phenytoin. Trimethoprim, given at a common clinical dosage, increased the phenytoin half-life by 51% and decreased the phenytoin metabolic clearance rate by 30%. When administering these drugs concurrently, one should be alert for possible excessive phenytoin effect.</p>
</div>
<div class="Section" data-sectionCode="34074-5">
<a name="LINK_ac0b75a8-168b-4f5d-ae60-7faad2404912"></a><a name="section-6.3"></a><p></p>
<h2>Drug/Laboratory Test Interactions</h2>
<p class="First">Trimethoprim can interfere with a serum methotrexate assay as determined by the Competitive Binding Protein Technique (CBPA) when a bacterial dihydrofolate reductase is used as the binding protein. No interference occurs, however, if methotrexate is measured by a radioimmunoassay (RIA).</p>
<p>The presence of trimethoprim may also interfere with the JaffÃ© alkaline picrate reaction assay for creatinine resulting in over estimations of about 10% in the range of normal values.</p>
</div>
<div class="Section" data-sectionCode="34083-6">
<a name="LINK_174d16de-6a21-4569-96a8-42e7ece77569"></a><a name="section-6.4"></a><p></p>
<h2>Carcinogenesis, Mutagenesis, Impairment of Fertility</h2>
<div class="Section" data-sectionCode="42229-5">
<a name="LINK_72329e76-ff78-43d1-b372-57c97cbb6ca5"></a><a name="section-6.4.1"></a><p></p>
<h3>Carcinogenesis</h3>
<p class="First">Long-term studies in animals to evaluate carcinogenic potential have not been conducted with trimethoprim.</p>
</div>
<div class="Section" data-sectionCode="42229-5">
<a name="LINK_f0a67d95-7154-43e3-a821-f47878a2705d"></a><a name="section-6.4.2"></a><p></p>
<h3>Mutagenesis</h3>
<p class="First">Trimethoprim was demonstrated to be nonmutagenic in the Ames assay. In studies at two laboratories, no chromosomal damage was detected in cultured Chinese hamster ovary cells at concentrations approximately 500 times human plasma levels; at concentrations approximately 1000 times human plasma levels in these same cells, a low level of chromosomal damage was induced at one of the laboratories. No chromosomal abnormalities were observed in cultured human leukocytes at concentrations of trimethoprim up to 20 times human steady-state plasma levels. No chromosomal effects were detected in peripheral <span class="product-label-link" type="condition" conceptid="4254663" conceptname="Lymphocyte count">lymphocytes</span> of human subjects receiving 320 mg of trimethoprim in combination with up to 1600 mg of sulfamethoxazole per day for as long as 112 weeks.</p>
</div>
<div class="Section" data-sectionCode="42229-5">
<a name="LINK_1e206a2d-2c78-46a5-a457-55a1f22d2542"></a><a name="section-6.4.3"></a><p></p>
<h3>Impairment of Fertility</h3>
<p class="First">No adverse effects on fertility or general reproductive performance were observed in rats given trimethoprim in oral dosages as high as 70 mg/kg/day for males and 14 mg/kg/day for females.</p>
</div>
</div>
<div class="Section" data-sectionCode="42228-7">
<a name="LINK_9cc11158-13e3-45f9-8ca4-a9f288960979"></a><a name="section-6.5"></a><p></p>
<h2>Pregnancy</h2>
<div class="Section" data-sectionCode="34077-8">
<a name="LINK_7aefd38e-a5e9-4dc1-a472-6b416f0e237c"></a><a name="section-6.5.1"></a><p></p>
<h3>Teratogenic Effects</h3>
<p class="First">Pregnancy Category C. Trimethoprim has been shown to be teratogenic in the rat when given in doses 40 times the human dose. In some rabbit studies, the overall increase in fetal loss (dead and resorbed and malformed conceptuses) was associated with doses six times the human therapeutic dose.</p>
<p>While there are no large, well-controlled studies on the use of trimethoprim in pregnant women, Brumfitt and Pursell, <span class="Sup">3</span> in a retrospective study, reported the outcome of 186 pregnancies during which the mother received either placebo or trimethoprim in combination with sulfamethoxazole. The incidence of congenital abnormalities was 4.5% (3 of 66) in those who received placebo and 3.3% (4 of 120) in those receiving trimethoprim and sulfamethoxazole. There were no abnormalities in the 10 children whose mothers received the drug during the first trimester. In a separate survey, Brumfitt and Pursell also found no congenital abnormalities in 35 children whose mothers had received trimethoprim and sulfamethoxazole at the time of conception or shortly thereafter.</p>
<p>Because trimethoprim may interfere with folic acid metabolism, trimethoprim should be used during pregnancy only if the potential benefit justifies the potential risk to the fetus.</p>
</div>
<div class="Section" data-sectionCode="34078-6">
<a name="LINK_d380d5e4-cf12-4bea-b081-59a886fa2cea"></a><a name="section-6.5.2"></a><p></p>
<h3>Nonteratogenic Effects</h3>
<p class="First">The oral administration of trimethoprim to rats at a dose of 70 mg/kg/day commencing with the last third of gestation and continuing through parturition and lactation caused no deleterious effects on gestation or pup growth and survival.</p>
</div>
</div>
<div class="Section" data-sectionCode="34080-2">
<a name="LINK_e2013133-e7e9-4d15-98b4-3fd298c82592"></a><a name="section-6.6"></a><p></p>
<h2>Nursing Mothers</h2>
<p class="First">Trimethoprim is excreted in human milk. Because trimethoprim may interfere with folic acid metabolism, caution should be exercised when trimethoprim is administered to a nursing woman.</p>
</div>
<div class="Section" data-sectionCode="34081-0">
<a name="LINK_a0c668b2-774e-4a69-b5ed-9bea862f4219"></a><a name="section-6.7"></a><p></p>
<h2>Pediatric Use</h2>
<p class="First">Safety and effectiveness in pediatric patients below the age of 2 months have not been established. The effectiveness of trimethoprim as a single agent has not been established in pediatric patients under 12 years of age.</p>
</div>
<div class="Section" data-sectionCode="34082-8">
<a name="LINK_a25647c2-e4ca-48a8-aadf-92c3180b2adb"></a><a name="section-6.8"></a><p></p>
<h2>Geriatric Use</h2>
<p class="First">Clinical studies of trimethoprim tablets did not include sufficient numbers of subjects aged 65 and over to determine whether they respond differently from younger subjects. Other reported clinical experience<span class="Sup">4,5</span> has not identified differences in response between the elderly and younger patients. In general, dose selection for an elderly patient should be cautious, usually starting at the low end of the dosing range, reflecting the greater frequency of decreased hepatic, renal or cardiac function, and of concomitant disease or other drug therapy.</p>
<p>Case reports of <span class="product-label-link" type="condition" conceptid="434610" conceptname="Hyperkalemia">hyperkalemia</span> in elderly patients receiving trimethoprim-sulfamethoxazole have been published.<span class="Sup">6</span> Trimethoprim is known to be substantially excreted by the kidney, and the risk of toxic reactions to this drug may be greater in patients with <span class="product-label-link" type="condition" conceptid="4030518" conceptname="Renal impairment">impaired renal function</span>. Because elderly patients are more likely to have decreased renal function, care should be taken in dose selection, and it may be useful to monitor potassium concentrations and to monitor renal function by calculating creatinine clearance.</p>
</div>
</div>
<div class="Section" data-sectionCode="34084-4">
<a name="LINK_0e0eec7c-85f3-4f76-92e1-ab138712228e"></a><a name="section-7"></a><p></p>
<h1>ADVERSE REACTIONS</h1>
<p class="First">The adverse effects encountered most often with trimethoprim were <span class="product-label-link" type="condition" conceptid="140214" conceptname="Eruption">rash</span> and <span class="product-label-link" type="condition" conceptid="4169287" conceptname="Itching of skin">pruritus</span>.</p>
<div class="Section" data-sectionCode="42229-5">
<a name="LINK_0c14b96b-769c-42bb-956c-6c1f170161aa"></a><a name="section-7.1"></a><p></p>
<h2>Dermatologic</h2>
<p class="First"><span class="product-label-link" type="condition" conceptid="140214" conceptname="Eruption">Rash</span>, <span class="product-label-link" type="condition" conceptid="4169287" conceptname="Itching of skin">pruritus</span>, and phototoxic <span class="product-label-link" type="condition" conceptid="140214" conceptname="Eruption">skin eruptions</span>. At the recommended dosage regimens of 100 mg b.i.d. or 200 mg q.d. each for 10 days, the incidence of <span class="product-label-link" type="condition" conceptid="140214" conceptname="Eruption">rash</span> is 2.9% to 6.7%. In clinical studies which employed high doses of trimethoprim, an elevated incidence of <span class="product-label-link" type="condition" conceptid="140214" conceptname="Eruption">rash</span> was noted. These <span class="product-label-link" type="condition" conceptid="140214" conceptname="Eruption">rashes</span> were maculopapular, morbilliform, pruritic, and generally mild to moderate, appearing 7 to 14 days after the initiation of therapy.</p>
</div>
<div class="Section" data-sectionCode="42229-5">
<a name="LINK_b907cbea-81a6-4c8e-a632-fae7f6022023"></a><a name="section-7.2"></a><p></p>
<h2><span class="product-label-link" type="condition" conceptid="4084167" conceptname="Acute allergic reaction">Hypersensitivity</span></h2>
<p class="First">Rare reports of <span class="product-label-link" type="condition" conceptid="4270887" conceptname="Erythroderma">exfoliative dermatitis</span>, <span class="product-label-link" type="condition" conceptid="132702" conceptname="Erythema multiforme">erythema multiforme</span>, <span class="product-label-link" type="condition" conceptid="141651" conceptname="Stevens-Johnson syndrome">Stevens-Johnson syndrome</span>, <span class="product-label-link" type="condition" conceptid="443754" conceptname="Lyell's toxic epidermal necrolysis, subepidermal type">toxic epidermal necrolysis</span> (<span class="product-label-link" type="condition" conceptid="4142366" conceptname="Ten">Lyell Syndrome</span>), and <span class="product-label-link" type="condition" conceptid="441202" conceptname="Anaphylaxis">anaphylaxis</span> have been received.</p>
</div>
<div class="Section" data-sectionCode="42229-5">
<a name="LINK_447dcf20-d6d2-4f22-b5e2-b0ab469d352d"></a><a name="section-7.3"></a><p></p>
<h2>Gastrointestinal</h2>
<p class="First"><span class="product-label-link" type="condition" conceptid="23325" conceptname="Heartburn">Epigastric distress</span>, <span class="product-label-link" type="condition" conceptid="31967" conceptname="Nausea">nausea</span>, <span class="product-label-link" type="condition" conceptid="441408" conceptname="Vomiting">vomiting</span>, and <span class="product-label-link" type="condition" conceptid="436147" conceptname="Glossitis">glossitis</span>. Elevation of serum transaminase and bilirubin has been noted, but the significance of this finding is unknown. <span class="product-label-link" type="condition" conceptid="4185719" conceptname="Cholestatic jaundice syndrome">Cholestatic jaundice</span> has been rarely reported.</p>
</div>
<div class="Section" data-sectionCode="42229-5">
<a name="LINK_97642327-167c-4a39-bcad-181ae44d581a"></a><a name="section-7.4"></a><p></p>
<h2>Hematologic</h2>
<p class="First"><span class="product-label-link" type="condition" conceptid="432870" conceptname="Thrombocytopenic disorder">Thrombocytopenia</span>, <span class="product-label-link" type="condition" conceptid="435224" conceptname="Leukopenia">leukopenia</span>, <span class="product-label-link" type="condition" conceptid="320073" conceptname="Neutropenia">neutropenia</span>, <span class="product-label-link" type="condition" conceptid="435789" conceptname="Megaloblastic anemia">megaloblastic anemia</span>, and <span class="product-label-link" type="condition" conceptid="432882" conceptname="Methemoglobinemia">methemoglobinemia</span>.</p>
</div>
<div class="Section" data-sectionCode="42229-5">
<a name="LINK_fab32fc1-ccb5-4aa9-83a1-4ed2ae65ade9"></a><a name="section-7.5"></a><p></p>
<h2>Metabolic</h2>
<p class="First"><span class="product-label-link" type="condition" conceptid="434610" conceptname="Hyperkalemia">Hyperkalemia</span>, <span class="product-label-link" type="condition" conceptid="4232311" conceptname="Hyponatremia">hyponatremia</span>.</p>
</div>
<div class="Section" data-sectionCode="42229-5">
<a name="LINK_14b8446c-ba19-4c0e-a807-6ba4ac318e3b"></a><a name="section-7.6"></a><p></p>
<h2>Neurologic</h2>
<p class="First"><span class="product-label-link" type="condition" conceptid="438418" conceptname="Non-pyogenic meningitis">Aseptic meningitis</span> has been rarely reported.</p>
</div>
<div class="Section" data-sectionCode="42229-5">
<a name="LINK_6309e765-57ea-4c1e-8c4e-f5d3b622dbd0"></a><a name="section-7.7"></a><p></p>
<h2>Miscellaneous</h2>
<p class="First"><span class="product-label-link" type="condition" conceptid="437663" conceptname="Fever">Fever</span>, and increases in BUN and serum creatinine levels.</p>
</div>
</div>
<div class="Section" data-sectionCode="34088-5">
<a name="LINK_bbb027eb-f654-4396-827e-f24b38c6e4b3"></a><a name="section-8"></a><p></p>
<h1>OVERDOSAGE</h1>
<div class="Section" data-sectionCode="42229-5">
<a name="LINK_a7f0551e-2aea-4fb4-aa6c-7d6bda4c2894"></a><a name="section-8.1"></a><p></p>
<h2>Acute</h2>
<p class="First">Signs of acute overdosage with trimethoprim may appear following ingestion of 1 gram or more of the drug and include <span class="product-label-link" type="condition" conceptid="31967" conceptname="Nausea">nausea</span>, <span class="product-label-link" type="condition" conceptid="441408" conceptname="Vomiting">vomiting</span>, <span class="product-label-link" type="condition" conceptid="4223938" conceptname="Dizziness">dizziness</span>, <span class="product-label-link" type="condition" conceptid="378253" conceptname="Headache">headaches</span>, mental <span class="product-label-link" type="condition" conceptid="438727" conceptname="Atypical depressive disorder">depression</span>, <span class="product-label-link" type="condition" conceptid="381273" conceptname="Confusional state">confusion</span> and <span class="product-label-link" type="condition" conceptid="4145241" conceptname="Bone marrow depression">bone marrow depression</span> (see<span class="Bold"><a href="#LINK_c2fd41ae-b8ab-45de-a22b-05a09bdcfe67">Chronic</a></span> subsection).</p>
<p>Treatment consists of gastric lavage and general supportive measures. Acidification of the urine will increase renal elimination of trimethoprim. Peritoneal dialysis is not effective and hemodialysis is only moderately effective in eliminating the drug.</p>
</div>
<div class="Section" data-sectionCode="42229-5">
<a name="LINK_c2fd41ae-b8ab-45de-a22b-05a09bdcfe67"></a><a name="section-8.2"></a><p></p>
<h2>Chronic</h2>
<p class="First">Use of trimethoprim at high doses and/or for extended periods of time may cause <span class="product-label-link" type="condition" conceptid="4145241" conceptname="Bone marrow depression">bone marrow depression</span> manifested as <span class="product-label-link" type="condition" conceptid="432870" conceptname="Thrombocytopenic disorder">thrombocytopenia</span>, <span class="product-label-link" type="condition" conceptid="435224" conceptname="Leukopenia">leukopenia</span> and/or <span class="product-label-link" type="condition" conceptid="435789" conceptname="Megaloblastic anemia">megaloblastic anemia</span>. If signs of <span class="product-label-link" type="condition" conceptid="4145241" conceptname="Bone marrow depression">bone marrow depression</span> occur, trimethoprim should be discontinued and the patient should be given leucovorin; 5 to 15 mg leucovorin daily has been recommended by some investigators.</p>
</div>
</div>
<div class="Section" data-sectionCode="34068-7">
<a name="LINK_7bba4444-18dd-4b9d-a51e-5cdb97a597ea"></a><a name="section-9"></a><p></p>
<h1>DOSAGE AND ADMINISTRATION</h1>
<p class="First">The usual oral adult dosage is 100 mg of trimethoprim every 12 hours or 200 mg trimethoprim (two 100 mg tablets) every 24 hours, each for 10 days. The use of trimethoprim in patients with a creatinine clearance of less than 15 mL/min is not recommended.</p>
<p>For patients with a creatinine clearance of 15 to 30 mL/min, the dose should be 50 mg every 12 hours.</p>
</div>
<div class="Section" data-sectionCode="34069-5">
<a name="LINK_08c18855-7b68-447b-b93d-b8ee390e06c7"></a><a name="section-10"></a><p></p>
<h1>HOW SUPPLIED</h1>
<p class="First">Trimethoprim Tablets USP, 100 mg are scored, oval-shaped, white tablets imprinted <span class="Bold">DAN DAN </span>and <span class="Bold">5571 </span>supplied in <br></p>
<a name="ie293dbd1-0689-4501-85dc-c768734a70b9"></a><table width="30%"><tbody class="Headless">
<tr class="First">
<td>Bottles of 30<br>
</td>
<td>NDC 54868-1616-1<br>
</td>
</tr>
<tr class="Last">
<td>Bottles of 20<br>
</td>
<td>NDC 54868-1616-4<br>
</td>
</tr>
</tbody></table>
<p>Dispense in a tight, light-resistant container with child-resistant closure.</p>
<p>Store at 20Â°-25Â°C (68Â°-77Â°F) in a dry place. [See USP controlled room temperature.]</p>
</div>
<div class="Section" data-sectionCode="34093-5">
<a name="LINK_16d64fee-457b-4f14-8664-7dfdd6d4293b"></a><a name="section-11"></a><p></p>
<h1>REFERENCES</h1>
<ol class="Arabic">
<li><p class="First">National Committee for Clinical Laboratory Standards. <span class="Italics">Methods for Dilution Antimicrobial Susceptibility Tests for Bacteria That Grow Aerobically. </span>3rd ed.; Approved Standard. NCCLS Document M7-A4, Vol. 17, No. 2, NCCLS, Wayne, PA, January, 1997.</p></li>
<li><p class="First">National Committee for Clinical Laboratory Standards. <span class="Italics">Performance Standards for Antimicrobial Disk Susceptibility Tests. </span>Sixth Edition. Approved Standard NCCLS Document M2-A6, Vol. 17, No. 1, NCCLS, Wayne, PA, January, 1997.</p></li>
<li><p class="First">Brumfitt W, Pursell R. Trimethoprim-sulfamethoxazole in the treatment of <span class="product-label-link" type="condition" conceptid="4265485" conceptname="Bacteriuria">bacteriuria</span> in women. <span class="Italics">J Infect Dis. </span>1973; 128 (suppl):S657-S663.</p></li>
<li><p class="First">Lacey RW, Simpson MHC, Fawcett C, et al. Comparison of single-dose trimethoprim with a five-day course for the treatment of <span class="product-label-link" type="condition" conceptid="81902" conceptname="Urinary tract infectious disease">urinary tract infections</span> in the elderly. Age and Ageing 10: 179-185, 1981.</p></li>
<li><p class="First">Ewer TC, Bailey RR, Gilchrist NL, et al. Comparative study of norfloxacin and trimethoprim for the treatment of elderly patients with <span class="product-label-link" type="condition" conceptid="81902" conceptname="Urinary tract infectious disease">urinary tract infection</span>. NZ Med J 101: 537-539, 1988.</p></li>
<li><p class="First">Marinella MA. Trimethoprim-induced <span class="product-label-link" type="condition" conceptid="434610" conceptname="Hyperkalemia">hyperkalemia</span>: An analysis of reported cases. Gerontology 45: 209-212, 1999.</p></li>
</ol>
<p class="First">Â Â Â Â Â Â Â Â Â Â Â Â Â Â Â Â Â Â Â Â Â Â Â Â Â Â Â Â Â Â Â Â Â Â Â Â Â Â Â Â Â Â Â Â Â Â Â Â Â Â Â Â Â Â Â Â Manufactured by:<br><span class="Bold">Â Â Â Â Â Â Â Â Â Â Â Â Â Â Â Â Â Â Â Â Â Â Â Â Â Â Â Â Â Â Â Â Â Â Â Â Â Â Â Â Â Â Â Â Watson Pharma Private Ltd.<br></span>Â Â Â Â Â Â Â Â Â Â Â Â Â Â Â Â Â Â Â Â Â Â Â Â Â Â Â Â Â Â Â Â Â Â Â Â Â Â Â Â Â Â Â Â Verna, Salcette Goa 403 722 INDIA</p>
<p>Â Â Â Â Â Â Â Â Â Â Â Â Â Â Â Â Â Â Â Â Â Â Â Â Â Â Â Â Â Â Â Â Â Â Â Â Â Â Â Â Â Â Â Â Â Â Â Â Â Â Â Â Â Â Â Â Distributed by:<br><span class="Bold">Â Â Â Â Â Â Â Â Â Â Â Â Â Â Â Â Â Â Â Â Â Â Â Â Â Â Â Â Â Â Â Â Â Â Â Â Â Â Â Â Â Â Â Â Â Watson Pharma, Inc.</span><span class="Bold"><br></span>Â Â Â Â Â Â Â Â Â Â Â Â Â Â Â Â Â Â Â Â Â Â Â Â Â Â Â Â Â Â Â Â Â Â Â Â Â Â Â Â Â Â Â Â Â Â Corona, CA 92880 USA</p>
<p>Revised: June 2009Â Â Â Â Â Â Â Â Â Â Â Â Â Â Â Â Â Â Â Â Â Â Â Â Â Â Â Â Â Â Â Â Â Â Â Â Â Â Â Â Â Â Â Â Â Â Â Â Â Â Â Â Â Â Â Â Â Â Â Â Â Â Â Â Â Â Â Â Â Â Â Â Â Â Â Â Â Â Â Â Â Â Â Â Â Â Â Â Â Â Â Â Â Â Â Â Â Â Â Â Â Â Â Â Â Â Â Â Â Â Â Â Â Â Â Â Â Â Â Â Â Â Â Â Â Â Â Â Â Â Â Â Â Â Â Â Â Â Â Â Â Â Â Â Â Â Â Â Â Â Â Â Â Â Â Â Â Â Â Â Â Â Â Â Â Â Â Â Â Â Â Â Â 190818<br>Â Â Â Â Â Â Â Â Â Â Â Â Â Â Â Â Â Â Â Â Â Â Â Â Â Â Â Â Â Â Â Â Â Â Â Â Â Â Â Â Â Â Â Â Â Â Â Â Â Â Â Â Â Â Â Â Â Â Â Â Â Â Â Â Â Â Â Â Â Â Â Â Â Â Â Â Â Â Â Â Â Â Â Â Â Â Â Â Â Â Â Â Â Â Â Â Â Â Â Â Â Â Â Â Â Â Â Â Â Â Â Â Â Â Â Â Â Â Â Â Â Â Â Â Â Â Â Â Â Â Â Â Â Â Â Â Â Â Â Â Â Â Â Â Â Â Â Â Â Â Â Â Â Â Â Â Â Â Â Â Â Â Â Â Â Â Â Â Â Â Â Â Â Â Â Â Â Â Â Â Â Â Â Â Â Â Â Â Â Â Â Â Â Â Â Â Â Â Â Â Â Â Â Â 0609B</p>
<div class="Section" data-sectionCode="42229-5">
<a name="section-11.1"></a><p></p>
<p class="First"><span class="Bold">Relabeling and Repackaging by:</span><br>Physicians Total Care, Inc.<br>Tulsa, OklahomaÂ Â Â Â Â Â  74146<br></p>
</div>
</div>
<div class="Section" data-sectionCode="51945-4">
<a name="LINK_58cdcaa5-15e0-4454-83d5-d026e22c0ca2"></a><a name="section-12"></a><p></p>
<h1>PRINCIPAL DISPLAY PANEL</h1>
<p class="First"><br>Trimethoprim<br>Tablets USP<br></p>
<p>100 mg<br>Rx Only</p>
<div class="Figure"><img alt="image of 100 mg package label" src="http://dailymed.nlm.nih.gov/dailymed/image.cfm?setid=7d25e3f9-7b0d-452d-953e-f100bb0f2db7&amp;name=1616.jpg"></div>
</div>
</div>
<div class="DataElementsTables">
<table class="contentTablePetite" cellSpacing="0" cellPadding="3" width="100%"><tbody>
<tr><td class="contentTableTitle">
<strong>TRIMETHOPRIMÂ 		
					</strong><br><span class="contentTableReg">trimethoprim tablet</span>
</td></tr>
<tr><td><table width="100%" cellpadding="5" cellspacing="0" class="formTablePetite">
<tr><td colspan="4" class="formHeadingTitle">Product Information</td></tr>
<tr class="formTableRowAlt">
<td class="formLabel">Product Type</td>
<td class="formItem">HUMAN PRESCRIPTION DRUG LABEL</td>
<td class="formLabel">Item Code (Source)</td>
<td class="formItem">NDC:54868-1616(NDC:0591-5571)</td>
</tr>
<tr class="formTableRow">
<td width="30%" class="formLabel">Route of Administration</td>
<td class="formItem">ORAL</td>
<td width="30%" class="formLabel">DEA Schedule</td>
<td class="formItem">Â Â Â Â 
							</td>
</tr>
</table></td></tr>
<tr><td><table width="100%" cellpadding="3" cellspacing="0" class="formTablePetite">
<tr><td colspan="3" class="formHeadingTitle">Active Ingredient/Active Moiety</td></tr>
<tr>
<th class="formTitle" scope="col">Ingredient Name</th>
<th class="formTitle" scope="col">Basis of Strength</th>
<th class="formTitle" scope="col">Strength</th>
</tr>
<tr class="formTableRowAlt">
<td class="formItem">
<strong>TRIMETHOPRIM</strong> (TRIMETHOPRIM) </td>
<td class="formItem">TRIMETHOPRIM</td>
<td class="formItem">100Â mg</td>
</tr>
</table></td></tr>
<tr><td><table width="100%" cellpadding="3" cellspacing="0" class="formTablePetite">
<tr><td colspan="2" class="formHeadingTitle">Inactive Ingredients</td></tr>
<tr>
<th class="formTitle" scope="col">Ingredient Name</th>
<th class="formTitle" scope="col">Strength</th>
</tr>
<tr class="formTableRowAlt">
<td class="formItem"><strong>ANHYDROUS LACTOSE</strong></td>
<td class="formItem">Â </td>
</tr>
<tr class="formTableRow">
<td class="formItem"><strong>SILICON DIOXIDE</strong></td>
<td class="formItem">Â </td>
</tr>
<tr class="formTableRowAlt">
<td class="formItem"><strong>MAGNESIUM STEARATE</strong></td>
<td class="formItem">Â </td>
</tr>
<tr class="formTableRow">
<td class="formItem"><strong>SODIUM LAURYL SULFATE</strong></td>
<td class="formItem">Â </td>
</tr>
<tr class="formTableRowAlt">
<td class="formItem"><strong>SODIUM STARCH GLYCOLATE TYPE A POTATO</strong></td>
<td class="formItem">Â </td>
</tr>
<tr class="formTableRow">
<td class="formItem"><strong>STEARIC ACID</strong></td>
<td class="formItem">Â </td>
</tr>
</table></td></tr>
<tr><td><table width="100%" cellpadding="3" cellspacing="0" class="formTablePetite">
<tr><td colspan="4" class="formHeadingTitle">Product Characteristics</td></tr>
<tr class="formTableRowAlt">
<td class="formLabel">Color</td>
<td class="formItem">WHITE</td>
<td class="formLabel">Score</td>
<td class="formItem">2 pieces</td>
</tr>
<tr class="formTableRow">
<td class="formLabel">Shape</td>
<td class="formItem">OVAL</td>
<td class="formLabel">Size</td>
<td class="formItem">13mm</td>
</tr>
<tr class="formTableRowAlt">
<td class="formLabel">Flavor</td>
<td class="formItem"></td>
<td class="formLabel">Imprint Code</td>
<td class="formItem">DAN;DAN;5571</td>
</tr>
<tr class="formTableRow">
<td class="formLabel">Contains</td>
<td class="formItem">Â Â Â Â </td>
</tr>
</table></td></tr>
<tr><td><table width="100%" cellpadding="3" cellspacing="0" class="formTablePetite">
<tr><td colspan="5" class="formHeadingTitle">Packaging</td></tr>
<tr>
<th scope="col" width="1" class="formTitle">#</th>
<th scope="col" class="formTitle">Item Code</th>
<th scope="col" class="formTitle">Package Description</th>
<th scope="col" class="formTitle">Marketing Start Date</th>
<th scope="col" class="formTitle">Marketing End Date</th>
</tr>
<tr class="formTableRowAlt">
<th scope="row" class="formItem">1</th>
<td class="formItem">NDC:54868-1616-1</td>
<td class="formItem">30  in 1 BOTTLE</td>
<td class="formItem"></td>
<td class="formItem"></td>
</tr>
<tr class="formTableRow">
<th scope="row" class="formItem">2</th>
<td class="formItem">NDC:54868-1616-4</td>
<td class="formItem">20  in 1 BOTTLE</td>
<td class="formItem"></td>
<td class="formItem"></td>
</tr>
</table></td></tr>
<tr><td></td></tr>
<tr><td class="normalizer"><table width="100%" cellpadding="3" cellspacing="0" class="formTableMorePetite">
<tr><td colspan="4" class="formHeadingReg"><span class="formHeadingTitle">Marketing Information</span></td></tr>
<tr>
<th scope="col" class="formTitle">Marketing Category</th>
<th scope="col" class="formTitle">Application Number or Monograph Citation</th>
<th scope="col" class="formTitle">Marketing Start Date</th>
<th scope="col" class="formTitle">Marketing End Date</th>
</tr>
<tr class="formTableRowAlt">
<td class="formItem">ANDA</td>
<td class="formItem">ANDA070049</td>
<td class="formItem">05/02/2012</td>
<td class="formItem"></td>
</tr>
</table></td></tr>
</tbody></table>
<table width="100%" cellpadding="3" cellspacing="0" class="formTableMorePetite"><tr><td colspan="4" class="formHeadingReg">
<span class="formHeadingTitle">Labeler -Â </span>Physicians Total Care, Inc.
							(194123980)
						</td></tr></table>
<table width="100%" cellpadding="3" cellspacing="0" class="formTableMorePetite">
<tr><td colspan="4" class="formHeadingReg"><span class="formHeadingTitle">Establishment</span></td></tr>
<tr>
<th scope="col" class="formTitle">Name</th>
<th scope="col" class="formTitle">Address</th>
<th scope="col" class="formTitle">ID/FEI</th>
<th scope="col" class="formTitle">Business Operations</th>
</tr>
<tr class="formTableRowAlt">
<td class="formItem">Physicians Total Care, Inc.</td>
<td class="formItem"></td>
<td class="formItem">194123980</td>
<td class="formItem">relabel, repack</td>
</tr>
</table>
</div>
<p><div class="EffectiveDate">Revised: 5/2012<div class="DocumentMetadata">
<div>
<a href="javascript:toggleMixin();">Document Id: </a>86e46afc-1269-4276-9985-2bb93fabd31e</div>
<div>Set id: 7d25e3f9-7b0d-452d-953e-f100bb0f2db7</div>
<div>Version: 2</div>
<div>Effective Time: 20120525</div>
</div>
</div>Â <div class="DistributorName">Physicians Total Care, Inc.</div></p>
</body></html>
